(NUS) Nu Skin Enterprises - Ratings and Ratios
Skincare, Devices, Nutritional, Collagen, Wellness
Dividends
| Dividend Yield | 2.43% |
| Yield on Cost 5y | 0.56% |
| Yield CAGR 5y | -36.75% |
| Payout Consistency | 96.6% |
| Payout Ratio | 7.3% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 58.0% |
| Value at Risk 5%th | 84.2% |
| Relative Tail Risk | -11.81% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.75 |
| Alpha | 19.92 |
| CAGR/Max DD | -0.42 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.448 |
| Beta | 0.983 |
| Beta Downside | 1.350 |
| Drawdowns 3y | |
|---|---|
| Max DD | 86.76% |
| Mean DD | 59.16% |
| Median DD | 70.60% |
Description: NUS Nu Skin Enterprises October 25, 2025
Nu Skin Enterprises, Inc. (NYSE:NUS) develops and distributes a portfolio of beauty and wellness products-including the ageLOC LumiSpa devices, Pharmanex nutritional supplements, and the ageLOC TR90 weight-management system-under the Nu Skin, Pharmanex and ageLOC brands. Sales are executed through a hybrid channel mix of direct-selling independent distributors, e-commerce platforms, and a limited network of retail locations.
Key performance metrics: FY 2023 net sales were $2.5 billion, up 5 % year-over-year, driven primarily by a 9 % increase in direct-seller-generated revenue; the company reported an adjusted EBITDA margin of 12 %, consistent with the personal-care sector average. The direct-selling force now numbers roughly 2.5 million active distributors worldwide, reflecting a modest 3 % growth from the prior year.
Sector drivers shaping Nu Skin’s outlook include sustained consumer spending on premium personal-care and wellness products, an aging global population that fuels demand for anti-aging solutions, and the continued shift toward online purchasing channels, which has accelerated post-COVID-19. Additionally, macro-level trends such as rising disposable income in emerging markets and heightened health consciousness in developed economies provide tailwinds for the company’s product mix.
For a deeper, data-rich assessment of Nu Skin’s valuation and risk profile, you may find ValueRay’s analytical tools useful as a next step in your research.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (109.6m TTM) > 0 and > 6% of Revenue (6% = 93.6m TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA -1.99pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 18.82% (prev 17.69%; Δ 1.13pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 89.5m <= Net Income 109.6m (YES >=105%, WARN >=100%) |
| Net Debt (39.6m) to EBITDA (191.8m) ratio: 0.21 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.15 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (50.3m) change vs 12m ago 1.16% (target <= -2.0% for YES) |
| Gross Margin 67.20% (prev 70.70%; Δ -3.51pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 103.8% (prev 112.1%; Δ -8.37pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 8.60 (EBITDA TTM 191.8m / Interest Expense TTM 15.8m) >= 6 (WARN >= 3) |
Altman Z'' 9.10
| (A) 0.21 = (Total Current Assets 548.1m - Total Current Liabilities 254.4m) / Total Assets 1.42b |
| (B) 1.30 = Retained Earnings (Balance) 1.85b / Total Assets 1.42b |
| warn (B) unusual magnitude: 1.30 — check mapping/units |
| (C) 0.09 = EBIT TTM 136.0m / Avg Total Assets 1.50b |
| (D) 2.77 = Book Value of Equity 1.73b / Total Liabilities 624.6m |
| Total Rating: 9.10 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 61.65
| 1. Piotroski 4.0pt |
| 2. FCF Yield 10.36% |
| 3. FCF Margin 3.42% |
| 4. Debt/Equity 0.36 |
| 5. Debt/Ebitda 0.21 |
| 6. ROIC - WACC (= 7.60)% |
| 7. RoE 14.65% |
| 8. Rev. Trend -95.57% |
| 9. EPS Trend -33.24% |
What is the price of NUS shares?
Over the past week, the price has changed by -1.10%, over one month by -7.21%, over three months by -17.93% and over the past year by +33.02%.
Is NUS a buy, sell or hold?
What are the forecasts/targets for the NUS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 7.5 | -24.2% |
| Analysts Target Price | 7.5 | -24.2% |
| ValueRay Target Price | 7.9 | -20.2% |
NUS Fundamental Data Overview November 25, 2025
P/E Trailing = 4.4658
P/E Forward = 7.0572
P/S = 0.313
P/B = 0.6108
P/EG = 2.35
Beta = 0.985
Revenue TTM = 1.56b USD
EBIT TTM = 136.0m USD
EBITDA TTM = 191.8m USD
Long Term Debt = 209.0m USD (from longTermDebt, last quarter)
Short Term Debt = 20.0m USD (from shortTermDebt, last quarter)
Debt = 291.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 39.6m USD (from netDebt column, last quarter)
Enterprise Value = 515.2m USD (476.8m + Debt 291.4m - CCE 253.0m)
Interest Coverage Ratio = 8.60 (Ebit TTM 136.0m / Interest Expense TTM 15.8m)
FCF Yield = 10.36% (FCF TTM 53.4m / Enterprise Value 515.2m)
FCF Margin = 3.42% (FCF TTM 53.4m / Revenue TTM 1.56b)
Net Margin = 7.02% (Net Income TTM 109.6m / Revenue TTM 1.56b)
Gross Margin = 67.20% ((Revenue TTM 1.56b - Cost of Revenue TTM 511.8m) / Revenue TTM)
Gross Margin QoQ = 70.49% (prev 68.82%)
Tobins Q-Ratio = 0.36 (Enterprise Value 515.2m / Total Assets 1.42b)
Interest Expense / Debt = 1.42% (Interest Expense 4.14m / Debt 291.4m)
Taxrate = -6.78% (negative due to tax credits) (-1.08m / 16.0m)
NOPAT = 145.2m (EBIT 136.0m * (1 - -6.78%)) [negative tax rate / tax credits]
Current Ratio = 2.15 (Total Current Assets 548.1m / Total Current Liabilities 254.4m)
Debt / Equity = 0.36 (Debt 291.4m / totalStockholderEquity, last quarter 799.8m)
Debt / EBITDA = 0.21 (Net Debt 39.6m / EBITDA 191.8m)
Debt / FCF = 0.74 (Net Debt 39.6m / FCF TTM 53.4m)
Total Stockholder Equity = 748.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.69% (Net Income 109.6m / Total Assets 1.42b)
RoE = 14.65% (Net Income TTM 109.6m / Total Stockholder Equity 748.2m)
RoCE = 14.21% (EBIT 136.0m / Capital Employed (Equity 748.2m + L.T.Debt 209.0m))
RoIC = 14.16% (NOPAT 145.2m / Invested Capital 1.03b)
WACC = 6.56% (E(476.8m)/V(768.2m) * Re(9.64%) + D(291.4m)/V(768.2m) * Rd(1.42%) * (1-Tc(-0.07)))
Discount Rate = 9.64% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.84%
[DCF Debug] Terminal Value 67.41% ; FCFE base≈68.3m ; Y1≈52.5m ; Y5≈32.9m
Fair Price DCF = 9.80 (DCF Value 477.7m / Shares Outstanding 48.8m; 5y FCF grow -27.52% → 3.0% )
EPS Correlation: -33.24 | EPS CAGR: -27.06% | SUE: 0.06 | # QB: 0
Revenue Correlation: -95.57 | Revenue CAGR: -15.12% | SUE: -0.84 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.27 | Chg30d=-0.050 | Revisions Net=-1 | Analysts=1
EPS current Year (2025-12-31): EPS=1.30 | Chg30d=+0.040 | Revisions Net=+1 | Growth EPS=+54.8% | Growth Revenue=-13.5%
EPS next Year (2026-12-31): EPS=1.42 | Chg30d=-0.140 | Revisions Net=-1 | Growth EPS=+9.2% | Growth Revenue=+2.1%
Additional Sources for NUS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle